GlassScriptPhysician profile
Marshea Liddell
NPI 1528473261
$10,236.12
in general payments reported to CMS, 2019-2025
32 companies · $2,727 in 2025
The $2,727 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,176 · 2022: $1,260 · 2023: $1,720 · 2024: $2,353 · 2025: $2,727.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,726 · Education: $74.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,725.91 |
| Education | $74.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,530.97 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,217.96 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $909.84 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $885.16 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Aimmune Therapeutics, INC. | $566.42 | 2024-2025 | Zenpep |
| Ardelyx, INC. | $546.39 | 2023-2025 | Ibsrela |
| Genzyme Corporation | $482.64 | 2023-2025 | |
| Nestle Healthcare Nutrition INC. | $314.32 | 2021-2023 | |
| Intercept Pharmaceuticals, INC. | $266.84 | 2021-2025 | Ocaliva |
| Ipsen Biopharmaceuticals, INC | $220.93 | 2025 | Iqirvo |
| Ironwood Pharmaceuticals, INC | $190.03 | 2021-2024 | Linzess |
| Celgene Corporation | $188.99 | 2022-2023 | Zeposia |
| Pfizer INC. | $143.33 | 2021-2023 | |
| Lilly USA, LLC | $140.88 | 2024-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $87.27 | 2024-2025 | Voquezna |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $74.96 | 2024 | |
| Horizon Therapeutics Plc | $56.80 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $49.68 | 2024-2025 | Dupixent |
| Redhill Biopharma INC. | $47.47 | 2021 | |
| Alnylam Pharmaceuticals INC. | $41.32 | 2024 | Givlaari |
| Gilead Sciences, INC. | $35.98 | 2021-2025 | |
| Evoke Pharma, INC. | $33.96 | 2021 | |
| Celltrion USA INC. | $33.31 | 2023-2025 | Vegzelma, Yuflyma |
| Qol Medical, LLC | $33.10 | 2021-2024 | Sucraid |
| Daiichi Sankyo INC. | $23.94 | 2021 | |
| Enterra Medical, INC. | $20.04 | 2023 | |
| Exact Sciences Corporation | $18.45 | 2023 | Cologuard Collection Kit |
| Impel Pharmaceuticals INC. | $17.90 | 2022 | |
| Novo Nordisk INC | $16.41 | 2025 | Saxenda, Wegovy |
| Medtronic, INC. | $14.01 | 2023 | Barrx |
| Madrigal Pharmaceuticals | $13.77 | 2025 | Rezdiffra |
| Braintree Laboratories, INC. | $13.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marshea Liddell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.